OVIOPEPTIDES
Research Use OnlyGet free bacteriostatic water added to your next order when you join the list.
TESAMORELIN - Image 1

TESAMORELIN

(34)
1
OVIO
PEPTIDES
Price
$80.00
99%+ Purity
3rd Party Tested
Fast Shipping
Discreet Package

Lab Results

Lab results available upon request
Research brief

Tesamorelin — Canada Research Brief

Last updated April 11, 2026

Tesamorelin is a synthetic GHRH analogue that stimulates endogenous growth hormone release, approved for HIV-associated lipodystrophy and studied in research settings for visceral adiposity and cognition.

Key facts

Canonical nameTesamorelin
Alternate namesEgrifta, TH9507, Egrifta SV
Drug classGrowth hormone releasing hormone (GHRH) analogue
CAS number218949-48-5
Molecular formulaC221H366N72O67S
Molecular weight5135.79 g/mol
Read full brief

Reconstitution Guide

Add bacteriostatic water to achieve your desired concentration:

1ml BAC water5.0mg/ml
2ml BAC water2.5mg/ml
2.5ml BAC water2.0mg/ml

Inject water slowly against vial wall. Swirl gently, do not shake.

About This Product

TESAMORELIN - Growth Hormone Releasing Hormone Analog for Research in Canada OVIOPEPTIDES offers premium TESAMORELIN in Canada for lipodystrophy research. This growth hormone releasing hormone analog is manufactured to the highest standards with 99%+ purity verification. PRODUCT OVERVIEW TESAMORELIN is a research-grade peptide compound available as lyophilized powder in a sealed glass vial. Modified GHRH that reduces visceral adipose tissue. RESEARCH APPLICATIONS Canadian researchers use TESAMORELIN for studies in: • Visceral fat • Lipodystrophy • Metabolic health • Cognitive function QUALITY ASSURANCE Every batch of TESAMORELIN from OVIOPEPTIDES undergoes rigorous third-party laboratory testing with HPLC purity analysis (99%+ verified), mass spectrometry confirmation, sterility testin...

Form

Lyophilized Powder

Quantity

5mg

Storage

-20°C

Share:

Customer Reviews (34)

Research brief

Tesamorelin — Canada Research Brief

Mechanism

Tesamorelin binds the GHRH receptor on somatotroph cells of the anterior pituitary, triggering pulsatile release of endogenous growth hormone (GH). Because it acts through the native GHRH axis, GH release remains subject to somatostatin-mediated negative feedback — an important distinction from exogenous recombinant GH, where the feedback loop is bypassed.

The N-terminal trans-3-hexenoyl modification blocks DPP-4 cleavage, the main metabolic route that limits the clinical usefulness of unmodified sermorelin. Subcutaneous bioavailability is modest (~4%), and the elimination half-life is approximately 26–38 minutes after a single dose.

Clinical evidence

Falutz et al. (NEJM 2007) reported the pivotal phase-3 trial in HIV- associated lipodystrophy: tesamorelin 2 mg subcutaneously daily reduced visceral adipose tissue by approximately 15% at 26 weeks versus placebo, with sustained IGF-1 elevation and a tolerable safety profile.

Baker et al. (Archives of Neurology 2012) investigated tesamorelin in older adults with mild cognitive impairment and healthy controls, finding improvement on executive-function measures over 20 weeks — the strongest trial-level evidence for cognitive effects of GHRH analogues in an ageing population.

Storage

Store lyophilised tesamorelin at −20°C protected from light. Once reconstituted, it should be used within 2–4 weeks when refrigerated at 2–8°C.

Frequently asked questions

What is tesamorelin?
Tesamorelin is a synthetic 44-amino-acid analogue of human growth hormone releasing hormone (GHRH) with an N-terminal trans-3-hexenoyl modification that protects it from dipeptidyl peptidase-4 (DPP-4) cleavage. It stimulates the anterior pituitary to release endogenous growth hormone and is approved in Canada as Egrifta for HIV-associated lipodystrophy.
Is tesamorelin approved in Canada?
Yes. Tesamorelin is approved by Health Canada as Egrifta for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Research-grade tesamorelin sold as a laboratory chemical is a separate, unapproved form for non-clinical laboratory research use only.
How is tesamorelin different from sermorelin and CJC-1295?
Sermorelin is GHRH (1-29), the active core of endogenous GHRH, with a short half-life measured in minutes. CJC-1295 adds tetrasubstitutions and, in the DAC variant, an albumin-binding moiety that extends half-life to 6–8 days. Tesamorelin is the full 44-residue GHRH with a single N-terminal acyl protection, giving it an intermediate half-life and a clinically established pharmacology.
What is tesamorelin's molecular weight?
Tesamorelin has a molecular weight of 5,135.79 g/mol, a molecular formula of C221H366N72O67S, and CAS number 218949-48-5.

References

  1. [1]Falutz J, Allas S, Blot K, et al.. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine, 2007. DOI: 10.1056/NEJMoa072375. PMID: 18057338
  2. [2]Baker LD, Barsness SM, Borson S, et al.. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults. Archives of Neurology, 2012. PMID: 22869065
  3. [3]National Center for Biotechnology Information. PubChem CID 16137828 — Tesamorelin, 2024

Related research

Frequently Asked Questions

What is TESAMORELIN used for in research?

TESAMORELIN is a growth hormone releasing hormone analog primarily used for lipodystrophy research. Modified GHRH that reduces visceral adipose tissue. Researchers study TESAMORELIN for its effects on visceral fat, lipodystrophy, metabolic health.

Can I buy TESAMORELIN in Canada?

Yes, OVIOPEPTIDES ships TESAMORELIN across all Canadian provinces including Ontario, British Columbia, Alberta, Quebec, Manitoba, Saskatchewan, and all territories. Our TESAMORELIN is available for non-clinical laboratory research purposes only.

What purity is your TESAMORELIN?

All TESAMORELIN from OVIOPEPTIDES is verified at 99%+ purity through independent third-party HPLC testing. Every order includes a Certificate of Analysis confirming purity, molecular weight, and identity verification.

How should I store TESAMORELIN?

Store lyophilized TESAMORELIN powder at -20°C (freezer) in its original sealed vial. Once reconstituted with bacteriostatic water, refrigerate at 2-8°C and use within 4 weeks. Avoid repeated freeze-thaw cycles.

How do I reconstitute TESAMORELIN?

To reconstitute TESAMORELIN, inject bacteriostatic water slowly against the vial wall. Swirl gently - never shake. Common reconstitution volumes are 1ml, 2ml, or 2.5ml depending on desired concentration. Allow the powder to dissolve completely before use.

Is TESAMORELIN legal in Canada?

TESAMORELIN is legal to purchase in Canada for non-clinical laboratory research purposes. It is not approved by Health Canada for therapeutic use and is not intended for human consumption. OVIOPEPTIDES sells TESAMORELIN strictly for research applications.

How does TESAMORELIN compare to sermorelin?

TESAMORELIN and sermorelin are both used in lipodystrophy research but have different mechanisms. TESAMORELIN is a growth hormone releasing hormone analog, while sermorelin may work through different pathways. Researchers often study these peptides together for comparative analysis.

What documentation comes with TESAMORELIN?

Every TESAMORELIN order from OVIOPEPTIDES includes a Certificate of Analysis (COA) documenting: HPLC purity results (99%+), mass spectrometry data, batch number, manufacturing date, and expiration date. This ensures full traceability for your research.